Date | 5 March 2021–present |
---|---|
Location | Nigeria |
Cause | COVID-19 pandemic |
Organised by | National Primary Health Care Development Agency |
Participants | |
Outcome | 8.4% of the Nigerian population received at least one dose [2] Contents3.8% of the Nigerian population fully vaccinated [2] |
Website | nphcda.gov.ng |
As of 28 February 2022 [update] |
Part of a series on the |
COVID-19 pandemic |
---|
|
COVID-19 portal |
COVID-19 vaccination in Nigeria is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country. Vaccination began on 5 March 2021. As of 28 February 2022, 17,914,944 people have received their first dose a COVID-19 vaccine, and 8,197,832 have received their second dose. [1]
On 2 March, the first shipment of four million Oxford–AstraZeneca COVID-19 vaccine doses from the COVAX initiative arrived at Nnamdi Azikiwe International Airport. [3]
Cyprian Ngong, a doctor at National Hospital, Abuja, became the first person in Nigeria to receive a COVID-19 vaccine on 5 March. [4] [5]
President Muhammadu Buhari received his first COVID-19 vaccine dose on 6 March. [6]
On 21 March, Nigeria received an additional 300,000 doses of Oxford–AstraZeneca COVID-19 vaccines from MTN. [7]
By the end of March, 0.7 million vaccine doses had been administered.[ citation needed ]
On 6 April, Nigeria received 100,000 doses of Oxford–AstraZeneca COVID-19 vaccines from the Government of India. [8]
By the end of April, 1.2 million vaccine doses had been administered.[ citation needed ]
By the end of May, 1.6 million vaccine doses had been administered.[ citation needed ]
By the end of June, 3.4 million vaccine doses had been administered.[ citation needed ]
The vaccination campaign in Nigeria was paused on 9 July due to exhaustion of the first COVAX shipment that arrived in March. [9] [10]
By the end of July, 3.9 million vaccine doses had been administered.[ citation needed ]
On 1 August, Nigeria received four million doses of Moderna COVID-19 vaccines from the United States. [11]
The second phase of the vaccination rollout began on 16 August. [12]
By the end of August, 4.2 million vaccine doses had been administered.
By the end of September, 6.9 million vaccine doses had been administered.
On 8 October, Nigeria received 500,000 doses of Oxford–AstraZeneca COVID-19 vaccines from the Government of France. [13]
By the end of October, 8.6 million vaccine doses had been administered. 4% of the target population had been fully vaccinated by the end of the month.
By the end of November, 9.8 million vaccine doses had been administered. 4% of the target population had been fully vaccinated by the end of the month.
Up to a million doses of the Oxford-AstraZeneca vaccine were destroyed by Nigeria due to their short expiry dates. [14]
By the end of December, 14.8 million vaccine doses had been administered. 5% of the target population had been fully vaccinated by the end of the month.
By the end of January, 20.6 million vaccine doses had been administered. 6% of the target population had been fully vaccinated by the end of the month.
By the end of February, 26.5 million vaccine doses had been administered and 8.1 million persons had been fully vaccinated.
By the end of March, 31.4 million vaccine doses had been administered and 9.6 million persons had been fully vaccinated.
By the end of April, 38.4 million vaccine doses had been administered and 14.9 million persons had been fully vaccinated.
Vaccine | Approval | Deployment |
---|---|---|
Oxford–AstraZeneca | Yes | Yes |
Moderna | Yes | Yes |
Janssen | Yes | No |
Sputnik V | Yes | No |
Pfizer–BioNTech | Yes | No |
Sinopharm BIBP | Yes | No |
Phase | Priority group | Progress |
---|---|---|
1 | Health workers and supporting staff, frontline workers and first responders | In progress |
2 | Priority 1: Persons aged 60 years and above. Priority 2: Persons aged 50–59 years | |
3 | Persons aged 18–49 years with co-morbidities | |
4 | The rest of the eligible population aged 18–49 years | |
Graphs are temporarily unavailable due to technical issues. |
Proportion vaccinated (1st dose) [lower-alpha 1]
Proportion vaccinated (2nd dose) [lower-alpha 2]
State | Total clients vaccinated (1st dose) | Total clients vaccinated (2nd dose) | Total clients vaccinated (booster dose) | |
---|---|---|---|---|
Moderna | Pfizer | |||
Abia | 178,606 | 104,979 | 1,052 | 15,352 |
Adamawa | 325,185 | 140,431 | 81 | 7,670 |
Akwa Ibom | 170,729 | 78,381 | 24 | 1,587 |
Anambra | 138,288 | 62,047 | 147 | 1,325 |
Bauchi | 322,583 | 128,349 | 698 | 4,240 |
Bayelsa | 57,895 | 23,222 | 202 | 726 |
Benue | 288,182 | 103,910 | 132 | 1,052 |
Borno | 200,699 | 73,697 | 85 | 2,766 |
Cross River | 354,326 | 172,314 | 298 | 15,539 |
Delta | 543,596 | 354,427 | 7,709 | 18,736 |
Ebonyi | 96,268 | 37,793 | 90 | 134 |
Edo | 208,074 | 97,024 | 1,042 | 1,642 |
Ekiti | 300,453 | 170,761 | 151 | 3,802 |
Enugu | 200,522 | 71,349 | 129 | 2,467 |
FCT | 453,323 | 253,528 | 1,821 | 18,282 |
Gombe | 238,851 | 136,204 | 638 | 20,256 |
Imo | 132,663 | 72,851 | 24 | 1,056 |
Jigawa | 2,391,500 | 716,180 | 109 | 16,638 |
Kaduna | 403,613 | 210,424 | 678 | 6,317 |
Kano | 1,797,509 | 698,910 | 6,550 | 140,078 |
Katsina | 446,009 | 150,495 | 474 | 7,564 |
Kebbi | 267,666 | 127,030 | 1,645 | 17,919 |
Kogi | 230,523 | 77,955 | 235 | 159 |
Kwara | 452,723 | 211,390 | 230 | 2,287 |
Lagos | 1,560,402 | 1,010,498 | 599 | 54,514 |
Nasarawa | 1,144,679 | 611,963 | 1,288 | 199,669 |
Niger | 363,643 | 139,411 | 89 | 3,117 |
Ogun | 942,275 | 499,162 | 338 | 16,326 |
Ondo | 412,164 | 204,788 | 98 | 2,994 |
Osun | 564,513 | 257,106 | 233 | 8,903 |
Oyo | 926,268 | 460,234 | 231 | 15,325 |
Plateau | 250,841 | 128,225 | 664 | 2,658 |
Rivers | 404,555 | 193,151 | 744 | 10,094 |
Sokoto | 234,880 | 76,227 | 52 | |
Taraba | 206,826 | 70,918 | 511 | 2,474 |
Yobe | 200,970 | 69,729 | 159 | 3,542 |
Zamfara | 503,142 | 202,589 | 359 | 40,085 |
COVID-19 Vaccines Global Access, abbreviated as COVAX, is a worldwide initiative aimed at equitable access to COVID-19 vaccines directed by the GAVI vaccine alliance, the Coalition for Epidemic Preparedness Innovations (CEPI), and the World Health Organization (WHO), alongside key delivery partner UNICEF. It is one of the four pillars of the Access to COVID-19 Tools Accelerator, an initiative begun in April 2020 by the WHO, the European Commission, and the government of France as a response to the COVID-19 pandemic. COVAX coordinates international resources to enable low-to-middle-income countries equitable access to COVID-19 tests, therapies, and vaccines. UNICEF is the key delivery partner, leveraging its experience as the largest single vaccine buyer in the world and working on the procurement of COVID-19 vaccine doses, as well as logistics, country readiness and in-country delivery.
The COVID-19 vaccination program in the Philippines is an ongoing mass immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country. The vaccination program was initiated by the Duterte administration on March 1, 2021, a day after the arrival of the country's first vaccine doses which were donated by the Chinese government.
The general COVID-19 vaccination in Australia program began on 22 February 2021 in response to the COVID-19 pandemic, with the goal of vaccinating all willing people in Australia before 2022. Front-line workers and aged care staff and residents had priority for being inoculated, before a gradual phased release to less-vulnerable and lower-risk population groups throughout 2021. The Therapeutic Goods Administration (TGA) approved four vaccines for Australian use in 2021: the Pfizer–BioNTech vaccine on 25 January, the Oxford–AstraZeneca vaccine on 16 February, Janssen vaccine on 25 June and the Moderna vaccine on 9 August. Although approved for use, the Janssen vaccine was not included in the Australian vaccination program as of June 2021.
On 29 January 2021, Algeria launched a COVID-19 vaccination campaign, a day after receiving its first shipment of 50,000 doses of the Russia's Sputnik V vaccine. As of 6 June 2021, around 2.5 million doses have been administered. Algeria is currently vaccinating its population with both Sputnik V and Oxford-AstraZeneca vaccines.
The COVID-19 vaccination in Morocco is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
COVID-19 vaccination in Angola is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country. As of 15 June 2021, Angola has administered 1,314,375 doses of vaccines.822,109 people with the first dose and 492,266 people fully vaccinated. Angola began their vaccination program shortly after receiving their first shipment of Oxford AstraZeneca vaccine in early March 2021.
COVID-19 vaccination in Botswana is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
Burkina Faso started vaccinating against COVID-19 on 2 June 2021.
Cape Verde has begun vaccinations against COVID-19.
On 23 February 2021, Senegal began its national vaccination program against the COVID-19. As of 10 March, 68,205 people in Senegal have been able to be vaccinated.
COVID-19 vaccination programs have begun in many countries and territories in Africa. In June 2021, the World Health Organization predicted that 47 of Africa's 54 nations would fall short of the aim of vaccinating 10% of their people by September 2021. In June, Africa accounted for fewer than 1% of worldwide vaccine doses delivered. Africa received in total less than 2% of the 3 billion vaccination doses provided globally.
COVID-19 vaccination in Ghana began on Monday 1 March 2021 after the country became the first recipient of the Oxford-AstraZeneca COVID-19 vaccine as part of the COVAX initiative. As of 6 June 2021, Ghana has administered 1,230,000 vaccine doses.
Bhutan has promised a free COVID-19 vaccination to all of its citizens, both inside and outside the country. It started mass vaccinations on 27 March 2021.
COVID-19 vaccination in Mexico is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
Bangladesh began the administration of COVID-19 vaccines on 27 January 2021 while mass vaccination started on 7 February 2021.
COVID-19 vaccination in Djibouti is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
COVID-19 vaccination in Egypt is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
COVID-19 vaccination in Eswatini is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
COVID-19 vaccination in the Democratic Republic of the Congo is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
The COVID-19 vaccination campaign began in Fiji on the first quarter of 2021 and will continue throughout the year with the goal of vaccinating all eligible Fijians. The government has made it mandatory for all eligible adults to take the COVID-19 vaccines.